Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Post by hmmmmmmmmon Sep 15, 2022 1:48pm
377 Views
Post# 34964916

The value of a NewCo..

The value of a NewCo..It was huge news in May when giants Medtronic (who was rumored last year to be interested in Dialco) and Davita (voted "most desperate to have their own pump") joined forces to create a NewCo focused on "In-Home Kidney care".

With Medtronic's tech might and DaVita's 200K+ patients it is quite a compelling venture.

BUT.. where's the pump(s)? These giants did not get together to create a consumables company. So where is it.

Imagine in Q1 when an IPO is announced for NewCo.. without a pump it's not very exciting- they will need to do a lot of heavy lifting to do to explain their roadmap and value propostion.

BUT imagine the NewCo IPO after they have aquired a FDA approved clinical use pump (SAMI) and a pump in the final months of it's FDA usability trial for In-Home use (DIMI).

What is their value then? Would that IPO double? triple? Would the difference literally be enough to pay for the aquisiton of the two pumps?

Remember- Davita has over 3,000 clinics they would sell their own SAMI pumps to. Add on 30% of their 200k patients enjoying new DIMI pumps at home...

Well, we'll see. Maybe next week...
<< Previous
Bullboard Posts
Next >>